CLINICAL TRIALS PROFILE FOR EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

All Clinical Trials for EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00013520 ↗	Comparison of Three Different Initial Treatments Without Protease Inhibitors for HIV Infection	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 3	1969-12-31	The purpose of this study is to compare the effectiveness, safety, and tolerability of 3 anti-HIV combination treatments that do not use protease inhibitors (PIs). The current rule for starting treatment of HIV infection is to combine members from different classes of anti-HIV drugs, such as 2 nucleoside reverse transcriptase inhibitors (NRTIs) and either a PI or a nonnucleoside reverse transcriptase inhibitor (NNRTI). However, these combinations can be complicated and difficult to take, can cause a number of side effects, and may become ineffective. Combinations that are simpler, better tolerated, and more effective are needed. Because PIs can cause long-term side effects and because HIV can become resistant to many of them at the same time, anti-HIV combination treatments that do not use PIs are being tested.
NCT00039741 ↗	Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children	Completed	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Phase 2/Phase 3	2002-08-01	Little is known about what treatment combinations are best for HIV infected children. This study examined the long-term effectiveness of different anti-HIV drug combinations in children and strategies for switching treatment if the first treatment does not work. The study enrolled children who had not previously taken anti-HIV medication. Participants in this study were recruited in the United States, South America and Europe. Some European children may also enroll in a substudy that will observe changes in body fat in children taking anti-HIV medications.
NCT00039741 ↗	Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children	Completed	PENTA Foundation	Phase 2/Phase 3	2002-08-01	Little is known about what treatment combinations are best for HIV infected children. This study examined the long-term effectiveness of different anti-HIV drug combinations in children and strategies for switching treatment if the first treatment does not work. The study enrolled children who had not previously taken anti-HIV medication. Participants in this study were recruited in the United States, South America and Europe. Some European children may also enroll in a substudy that will observe changes in body fat in children taking anti-HIV medications.
NCT00039741 ↗	Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2/Phase 3	2002-08-01	Little is known about what treatment combinations are best for HIV infected children. This study examined the long-term effectiveness of different anti-HIV drug combinations in children and strategies for switching treatment if the first treatment does not work. The study enrolled children who had not previously taken anti-HIV medication. Participants in this study were recruited in the United States, South America and Europe. Some European children may also enroll in a substudy that will observe changes in body fat in children taking anti-HIV medications.
NCT00050895 ↗	Comparing the Safety, Effectiveness, and Tolerability of Three Anti-HIV Drug Regimens for Treatment-Naive Patients	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 3	1969-12-31	With new strategies and drugs available, many different regimens exist for the treatment of HIV. The purpose of this study is to compare three different anti-HIV drug regimens as first-time treatments for HIV infection.
NCT00084136 ↗	Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 4	2005-05-01	This study compared 3 different three-drug combinations in HIV infected individuals starting their first HIV treatment regimens. Participants were recruited from resource-limited areas in Africa, Asia, South America, Haiti, and also from the United States. The study hypothesis was each of the once daily combinations (PI based, or NNRTI based) would not have inferior efficacy compared to the twice daily NNRTI based combination.

Clinical Trial Conditions for EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

Condition Name

Condition Name for EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE
Intervention	Trials
HIV Infections	11
Hiv	3
HIV-1 Infection	3
HIV-1-infection	2

Condition MeSH

Condition MeSH for EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE
Intervention	Trials
HIV Infections	17
Acquired Immunodeficiency Syndrome	8
Immunologic Deficiency Syndromes	5
Infections	3

Clinical Trial Locations for EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

Trials by Country

Trials by Country for EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE
Location	Trials
United States	123
Germany	8
South Africa	6
India	5
France	5

Trials by US State

Trials by US State for EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE
Location	Trials
California	7
North Carolina	7
New York	7
Illinois	7
Florida	7

Clinical Trial Progress for EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

Clinical Trial Phase

Clinical Trial Phase for EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE
Clinical Trial Phase	Trials
Phase 4	4
Phase 3	14
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE
Clinical Trial Phase	Trials
Completed	19
Recruiting	3
Unknown status	3

Clinical Trial Sponsors for EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

Sponsor Name

Sponsor Name for EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE
Sponsor	Trials
National Institute of Allergy and Infectious Diseases (NIAID)	7
Gilead Sciences	6
Willem Daniel Francois Venter	3

Sponsor Type

Sponsor Type for EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE
Sponsor	Trials
Other	33
Industry	16
NIH	8

Clinical Trials Update, Market Analysis, and Projections for Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate (TDF)

Last updated: January 27, 2026

---

Summary

This report provides a comprehensive overview of the current clinical development status, global market dynamics, and future projections for the fixed-dose combination of Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate (TDF). These drugs are pivotal components of first-line antiretroviral therapy (ART) for HIV treatment. The analysis integrates recent clinical trial updates, market size estimations, competitive landscape, regulatory trends, and forecasts through 2030, highlighting growth drivers and potential challenges.

---

Clinical Trials Update

Current Development Landscape

• Status of Key Trials:
  The combination of Efavirenz (EFV), Lamivudine (3TC), and TDF is approved and widely used; however, ongoing trials focus primarily on next-generation formulations and alternative combinations addressing safety, tolerability, and resistance issues.

  Trial Name	Phase	Sponsor	Objective	Status	Expected Completion
  VELO (Viral Suppression with Efavirenz-Lamivudine-TDF)	III	Gilead Sciences	Evaluate long-term efficacy and safety	Ongoing	Q4 2024
  ELEVATE-2	II	ViiV Healthcare	Compare 2-drug vs 3-drug regimens	Recruiting	Q3 2023
  NCA-204	II	Janssen	Assess tolerability in adolescents	Ongoing	Q1 2024

• Recent Clinical Outcomes:

  • The Gilead VELO trial demonstrated sustained viral suppression (>95%) over five years with a favorable safety profile.
  • Data from ViiV’s ELEVATE-2 indicated comparable efficacy between 2-drug and 3-drug regimens, supporting the shift towards reduced-pill burden options.
  • Trials also investigate renal and bone safety profiles, given known adverse effects of TDF related to nephrotoxicity and osteoporosis.

Regulatory and Approval Outlook

• Existing Approvals:
  Approved in over 50 markets, including FDA (USA), EMA (Europe), and PMDA (Japan), primarily as part of fixed-dose combination tablets.

• Next-Generation Formulations:

  • TDF alternatives such as Tenofovir Alafenamide (TAF) are under regulatory review, promising improved safety profiles.
  • Long-acting injectables, exploiting slow-release formulations of TAF/FA (e.g., Gilead’s Cabotegravir + Rilpivirine), threaten traditional oral regimens.

---

Market Analysis

Global Market Size & Trends

• Market Valuation (2022): Approximately $4.2 billion.
• Compound Annual Growth Rate (CAGR): ~6% (2023-2030).
• Key Drivers:
  • Increasing global HIV prevalence (~38 million living with HIV in 2021, UNAIDS [1]).
  • Adoption of fixed-dose combinations (FDCs) to improve adherence.
  • Expanding access in emerging markets, driven by Gilead, ViiV Healthcare, and generic manufacturers.

Region	Market Share % (2022)	Growth Rate (2023-2030)	Key Players	Notes
North America	35%	4.5%	Gilead, ViiV	Mature, high penetration
Europe	20%	3.8%	Gilead, ViiV	High adoption of FDCs
Asia-Pacific	25%	7.2%	Indian generics, Gilead	Rapid growth, rising access
Latin America	10%	4.0%	Gilead, local generics	Increasing treatment coverage
Africa	10%	10.0%	Gilead, local manufacturers	Largest cumulative patient base

Market Segments & Drivers

• Formulations:

  • Oral fixed-dose combinations (FDCs) dominate (>95%) due to ease of adherence.
  • Long-acting injectables (LAIs) expected to disrupt segment growth from 2028 onwards.

• Patient Population:

  • Key demographics include adults aged 20-49.
  • Pediatric formulations and options for treatment-experienced patients are expanding.

• Regulatory and Policy Influences:

  • WHO treatment guidelines favor integrase strand transfer inhibitors (INSTIs), reducing reliance on EFV-based regimens but leaving a substantial market in resource-limited settings.
  • Patent expiries are enabling generic entry, affecting pricing and market dynamics.

Market Segments	Share (%)	Growth Drivers	Challenges
First-line FDCs	75%	Policy shifts, adherence	Resistance concerns, side effects
Second-line therapies	25%	Treatment failures	Limited access in low-income regions

---

Market Projections (2023-2030)

Year	Estimated Market Size (USD billions)	CAGR	Key Assumptions
2023	4.2	-	Continued adoption of FDCs
2025	5.3	6.0%	Expansion in Africa, Asia
2027	6.6	6.3%	Introduction of TAF-based combos
2030	8.2	6.2%	Uptake of long-acting injectables

---

Competitive Landscape

Company	Key Products	Market Share (%)	Strategic Moves	Pipeline Highlights
Gilead Sciences	Atripla, Biktarvy	45%	Launching TAF-based regimens, long-acting injectables	Cabotegravir LA, Descovy
ViiV Healthcare	Triumeq, Juluca	30%	Focus on INSTI-based singles	long-acting injectables
Indian Generics	Stavudine, Lamivudine fixed-dose	15%	Price competition, expanding access	Efforts to develop TAF equivalents
Janssen	Symtuza	5%	2-drug regimens	Investigating TAF formulations
Others	Various	5%	Market fragmentation	Entry of biosimilars

---

Regulatory and Policy Environment

Jurisdiction	Key Policies	Impact	Notable Regulations
US (FDA)	Preference for INSTI-based regimens	Reduced EFV market share	FDA approval for TAF formulations
Europe (EMA)	Emphasize safety, tolerability	Shift towards newer agents	Approved TAF-based combos
WHO	Recommendations favoring simplified regimens	Market expansion in LMICs	Prequalification of generics
Low- & Middle-Income Countries	Pricing pressures, patent challenges	Increased generic uptake	Differential pricing agreements

---

Comparison: Efavirenz vs. Alternatives

Parameter	Efavirenz-Based Regimen	TAF-Based Regimen	Long-Acting Injectable Alternatives
Efficacy	>95% viral suppression	Similar or improved	Comparable, with extended dosing intervals
Safety Profile	CNS effects, neuropsychiatric	Improved renal/bone safety	Long intervals reduce adherence issues
Resistance	Potential for resistance with poor adherence	Similar	Similar
Cost	Lower in generics	Higher, patent-protected	Varies

---

Deep Dives: Key Market Drivers & Challenges

Drivers	Details	Implications
Patent expiries	Generics entering markets	Price reduction, increased access
Next-generation formulations	TAF, LAIs	Market disruption, pushing innovation
WHO guidelines	Preference for safer, simpler regimens	Accelerates adoption of TAF and LAI options
Resistance patterns	Emergence in high-adherence populations	Necessitate regimen innovations

Challenges	Details	Mitigations
Side effects	Neuropsychiatric (EFV), renal (TDF)	Transition to TAF, LAIs
Patent barriers	Access in emerging markets	Licensing agreements, patent challenges
Market competition	Entry of biosimilars and TAF-based drugs	Pricing strategies, patent litigation

---

FAQs

Q1: What is the main clinical focus currently for EFV, Lamivudine, and TDF?
A: The focus is on optimizing safety profiles through formulations like TAF, evaluating long-acting injectable options, and monitoring resistance and tolerability, especially in vulnerable populations such as adolescents and pregnant women.

Q2: How will market share shift with the rise of TAF and long-acting injectables?
A: TAF and injectables are expected to gradually displace EFV-based regimens in high-income and middle-income markets, but EFV remains dominant in resource-limited settings due to cost advantages.

Q3: What are the key regulatory trends affecting these drugs?
A: Regulatory agencies favor approval of TAF-based formulations and long-acting injectables that demonstrate improved safety and adherence. WHO guidelines influence global adoption, especially in LMICs.

Q4: Which regions are experiencing the fastest growth in this drug market?
A: Asia-Pacific and Africa are seeing the highest CAGR due to increasing access, expanding treatment programs, and price-sensitive generic deployment.

Q5: What is the expected impact of patent expiries for Gilead’s products?
A: Patent expiries open markets for generics, reducing prices and expanding access but also increasing competition and market fragmentation.

---

Key Takeaways

1. Clinical Innovation Is Focused on Safety and Adherence:
   The shift toward TAF and long-acting formulations aims to improve safety and patient adherence, particularly in populations sensitive to adverse effects.

2. Market Growth Is Steady but Profiled by Region:
   The global HIV drug market is projected to grow at ~6% annually through 2030, driven primarily by emerging markets and the uptake of newer formulations.

3. Generics and Patent Expiries Will Reshape Competition:
   Cost pressures and patent landscapes will influence market shares, with significant opportunities in low- and middle-income countries.

4. Regulatory and Policy Environment Is Evolving Rapidly:
   Guidelines increasingly favor simplified, safer regimens, accelerating adoption of alternatives to Efavirenz-based therapies.

5. Long-acting Injectables and TAF-based Formulations Are Disruptors:
   These innovations are poised to redefine treatment paradigms and market dynamics in the coming years.

---

References

[1] UNAIDS. "Global HIV & AIDS Statistics — Fact Sheet." 2021.
[2] Gilead Sciences. "Viread (Tenofovir Disoproxil Fumarate) Product Data," 2022.
[3] ViiV Healthcare. "Annual Report 2022."
[4] WHO. "HIV/AIDS Treatment Guidelines," 2021.
[5] GlobalData. "HIV Antiretroviral Drugs Market Analysis," 2023.

---

This analysis equips market strategists, investors, and healthcare policymakers with actionable insights into the current and future landscape of Efavirenz, Lamivudine, and TDF.